TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Moderna and Merck say their personalized mRNA vaccine, intismeran, combined with Keytruda reduced the risk of melanoma recurrence or death by 42% compared with Keytruda and placebo in a Phase 3 trial. At two years, 82% of patients in the vaccine group were alive without recurrence, versus 70% in the comparison group; the companies’ announcement does not establish that the treatment is approved or available.
Moderna and Merck say their personalized mRNA cancer vaccine, intismeran, reduced the risk of melanoma recurrence or death when given with Keytruda, compared with Keytruda and placebo, in a Phase 3 trial. At two years, 82% of patients who received the combination were alive without recurrence, against 70% in the comparison group, according to the companies’ announcement.
The reported 42% reduction refers to the relative risk of recurrence or death in the combination group compared with the Keytruda-and-placebo group. It is not a 42-percentage-point difference in the share of patients who remained recurrence-free: the reported two-year figures were 82% versus 70%. The trial measured recurrence-free survival, the time patients lived without their cancer returning.
The companies also reported a 38% reduction in the risk of distant metastasis or death, compared with Keytruda and placebo. Distant metastasis means cancer has spread to a part of the body away from where it began. At the reported endpoint, 88.5% of the vaccine group were alive without distant metastasis, compared with 80% of the comparison group.
Intismeran, also known as mRNA-4157, is designed for each patient. It uses synthetic mRNA encoding up to 34 mutations identified by comparing a patient’s tumor with healthy cells. The intent is to prompt an immune response against cancer-specific features. The regimen was tested alongside Keytruda (pembrolizumab), Merck’s immunotherapy; the reported comparison was not against no treatment.
A Potential Addition After Melanoma Surgery
The results could matter to people with resected melanoma—melanoma removed by surgery—who receive treatment afterward to lower the chance of the cancer returning. The findings suggest a personalized vaccine may add benefit to an existing immunotherapy regimen in this setting. However, the figures describe outcomes in a clinical trial, not a guarantee for an individual patient or proof that the vaccine is ready for routine use.
The reported percentages also need to be read alongside their comparison. The 42% figure is a relative reduction in risk, while the two-year recurrence-free proportions differed by 12 percentage points. Those measures answer related but distinct questions. The results provide a new Phase 3 data point for a tailored cancer vaccine approach, but further information is needed to judge the size and durability of its benefit and how it may fit into treatment decisions.
Products Worth Considering
Withings Body Smart Wi-Fi and Bluetooth Smart Scale
Blueair Blue Pure 511i Max Air Purifier
Garmin Venu 3 Fitness Smartwatch, 45 mm, Black
As an affiliate, we earn on qualifying purchases.
How the Personalized Vaccine Works
Unlike a vaccine aimed at a shared feature of a virus, intismeran is built using genetic information from an individual patient’s tumor. Researchers compare tumor and healthy-cell sequences, select mutations found in the cancer, and use the selected coding to create the mRNA formulation. The approach is intended to help the immune system distinguish cancer cells from healthy cells; the reported trial results do not mean every patient’s tumor will produce the same vaccine or response.
The new Phase 3 findings follow a smaller five-year Phase 2 trial cited in the source report. That earlier study reported a 49% reduction in recurrence-or-death risk and a 59% reduction in distant-metastasis-or-death risk. The newer reported figures are smaller, and comparisons between trials should be cautious because study design, follow-up and patient groups can affect outcomes. The Phase 3 trial compared the vaccine combination with Keytruda plus placebo.
“The trial “is the first Phase 3 study to demonstrate a clinically meaningful improvement in RFS and DMFS over standard-of-care KEYTRUDA in patients with resected melanoma.””
— Dean Li, president of Merck Research Laboratories, in the companies’ announcement
Approval and Long-Term Outcomes Remain Open
The announcement as described in the source does not establish whether regulators have approved intismeran, when a decision might come, or whether the vaccine is available to patients outside a clinical trial. It also does not provide the full study report, including detailed methods, participant numbers, confidence intervals, statistical significance, or a complete account of adverse events. Those details are needed to assess the results and the treatment’s risks alongside its potential benefit.
Although the companies reported outcomes at two years, the extent to which the benefit persists with longer follow-up is not yet clear from the available information. The reported measures combine recurrence or metastasis outcomes with death, and the figures do not show how results varied across patient subgroups. It also remains uncertain how clinicians might select patients for a personalized vaccine if it becomes an approved option.
Full Trial Data and Regulatory Review
The next developments to watch are publication of the complete Phase 3 results and any regulatory submissions or decisions. A full report would allow clinicians and researchers to examine the trial population, follow-up, statistical analysis, safety findings and the precise definition of the reported endpoints. Until those details and any approval status are clear, the results should be treated as a promising company-reported trial finding rather than a change in standard care.
Patients with melanoma should discuss established treatment options and clinical-trial eligibility with their oncology team. The announcement alone does not indicate that an individual patient should alter or delay treatment.
Key Questions
What does the reported 42% reduction mean?
It is the reported relative reduction in risk of recurrence or death for patients receiving intismeran plus Keytruda compared with Keytruda and placebo. At two years, 82% of the combination group were alive without recurrence, compared with 70% of the comparison group.
Was the vaccine tested on its own?
No. The reported Phase 3 comparison was intismeran plus Keytruda against Keytruda plus placebo. The result describes the added effect of the vaccine within that treatment combination.
What is intismeran?
Intismeran, also called mRNA-4157, is a personalized mRNA vaccine designed using mutations identified in a patient’s tumor. The reported approach selects cancer-specific genetic features to help direct an immune response.
Is the vaccine approved for melanoma treatment?
The source material reports trial results and a company announcement, but does not establish regulatory approval or availability. Patients should ask their oncology team about current approved care and relevant clinical trials.
Source: hn
